Palmar plantar erythrodysesthesia historical perspective: Difference between revisions
Mchitsazan (talk | contribs) No edit summary |
Mchitsazan (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Palmar plantar erythrodysesthesia}} | |||
{{CMG}}, {{AE}} {{MC}} | {{CMG}}, {{AE}} {{MC}} | ||
Revision as of 16:59, 2 July 2019
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia historical perspective On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia historical perspective |
|
FDA on Palmar plantar erythrodysesthesia historical perspective |
|
CDC on Palmar plantar erythrodysesthesia historical perspective |
|
Palmar plantar erythrodysesthesia historical perspective in the news |
|
Blogs on Palmar plantar erythrodysesthesia historical perspective |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
In 1974, Zuehlke was the first to describe PPE in a patient receiving mitotane for hypernephroma.
Historical Perspective
In 1974, Zuehlke was the first to describe PPE in a patient receiving mitotane for hypernephroma.[1]
References
- ↑ R. L. Zuehlke. "Erythematous eruption of the palms and soles associated with mitotane therapy". Dermatologica. PMID 4276191.